Bora Pharmaceuticals Renews $250M CDMO Deal with GSK

- This partnership originated when Bora Pharmaceuticals acquired the primary manufacturing facility in Mississauga, Ontario, from GSK in 2020; GSK remains the largest client at that site. - The agreement extends beyond the initial summary, covering end-to-end manufacturing for over 335 individual products and more than 20 commercial GSK product lines. These products address a wide range of indications, including pneumonia, depression, migraine, and various skin conditions, in addition to HIV and malaria. - As part of the renewed deal, GSK gains access to a broader network of Bora's manufacturing sites, including a new oral solid dose facility in Maple Grove, Minnesota, enhancing supply chain redundancy. - The Mississauga facility features 18 highly configurable manufacturing modules and has capabilities for producing tablets, capsules, nasal sprays, creams, and other semi-solid and liquid therapeutics. Since Bora's acquisition, the site has supported 32 clients and completed more than 400 development and project batches. - This deal aligns with GSK's broader strategy of divesting physical manufacturing assets while investing in digital transformation, AI, and advanced analytics to create a more resilient and predictive supply chain. - For Bora, this renewal provides stable revenue and supports its strategy of North American expansion, which has recently included acquiring a sterile manufacturing facility in Baltimore and expanding capacity for dermatological products in Canada. - The global pharmaceutical CDMO market is projected to grow from approximately $273 billion in 2026 to over $580 billion by 2034, driven by pharmaceutical companies outsourcing to gain cost efficiencies and access to specialized technologies.